Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Epilepsy 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 8Nivolumab 8Biopsy 7Radiotherapy 6Temozolomide 4Specimen Handling 4Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Aspirin 3perflutren 2alovudine 2Tirzepatide 2Rituximab 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Immunotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × brivaracetam × 90 days × Clear all
NCT05029960 2026-06-03

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

University of Rochester

Phase EARLY_PHASE1 Terminated
3 enrolled
CNS

Brain Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡